TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01886027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Awareness and Expression Training
Description: An emotional processing intervention, which aims to reduce stress by helping patients become aware of, and express emotions related to stressful life experiences, as well as teaching patients how to relate to others differently.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Training
Description: Teaches patients different relaxation training skills to reduce their distress and discomfort (i.e., progressive muscle relaxation, applied relaxation, or guided imagery.
Study: NCT02866344

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic resection
Description: Laparoscopic or robot-assisted laparoscopic surgical resection of cancerous lesions.
Study: NCT04357171

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low anterior resection with protective loop ileostomy
Description: Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta or right below left colic artery. Nerve-sparing total mesorectal excision is performed. Side-to-end sigmoido-rectal anastomosis is created. A loop defunctioning ileostomy is performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low anterior resection with protective loop transverse colostomy
Description: Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta or right below left colic artery. Nerve-sparing total mesorectal excision is performed. Side-to-end sigmoido-rectal anastomosis is created. A loop defunctioning transverse colostomy is performed.
Study: NCT04002167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: The Neurofeedback group will receive the proposed intervention which integrates computerized working memory training with neuromonitoring and neurofeedback.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: The Cognitive training group will receive computerized working memory training with performance feedback.
Study: NCT02168582

Intervention type: BEHAVIORAL
Intervention: physiotherapy as usual in primary care
Study: NCT03784196

Intervention type: OTHER
Intervention: Conservative rehabilitation
Description: WAD participants underwent 2-weeks rehabilitation.
Study: NCT01908348

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Erythritol
Study: NCT03973450

Intervention type: OTHER
Intervention: Registration of familial forms and associated neoplasia
Description: Retrospective registration of associated endocrine and non-endocrine neoplasia and potential familial setting
Study: NCT01085188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACC
Description: Weekly community based behavioral counseling and case management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACC
Description: Weekly community based behavioral counseling and case management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CM
Description: Weekly community based prize drawing opportunities contingent upon completed verifiable pro-social activities and clean urine and breath alcohol test results

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CM
Description: Weekly community based prize drawing opportunities contingent upon completed verifiable pro-social activities and clean urine and breath alcohol test results

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UCC
Description: recommendation made by discharge counselor upon leaving residential treatment to attend nearest outpatient clinic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UCC
Description: recommendation made by discharge counselor upon leaving residential treatment to attend nearest outpatient clinic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UCC
Description: recommendation made by discharge counselor upon leaving residential treatment to attend nearest outpatient clinic.
Study: NCT02926677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: The control group. The standard treatment utilized at Stanford Youth Solutions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRScout
Description: The device is a portable Functional Near-Infrared Spectroscopy (fNIRS) recording unit. NIRS technology uses specific wavelengths of light, introduced at the scalp to enable the non-invasive measurement of changes in the relative ratios of deoxygenated hemoglobin (deoxy-Hb) and oxygenated hemoglobin (oxy-Hb) in the capillary beds during brain activity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRScout
Description: The device is a portable Functional Near-Infrared Spectroscopy (fNIRS) recording unit. NIRS technology uses specific wavelengths of light, introduced at the scalp to enable the non-invasive measurement of changes in the relative ratios of deoxygenated hemoglobin (deoxy-Hb) and oxygenated hemoglobin (oxy-Hb) in the capillary beds during brain activity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRScout
Description: The device is a portable Functional Near-Infrared Spectroscopy (fNIRS) recording unit. NIRS technology uses specific wavelengths of light, introduced at the scalp to enable the non-invasive measurement of changes in the relative ratios of deoxygenated hemoglobin (deoxy-Hb) and oxygenated hemoglobin (oxy-Hb) in the capillary beds during brain activity.
Study: NCT02783352

Intervention type: PROCEDURE
Group type: OTHER
Intervention: arthroscopic rotator cuff repair
Description: arthroscopic rotator cuff repair
Study: NCT02776319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive brain stimulation (active)
Description: Non-invasive brain stimulation (active)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-invasive brain stimulation (sham)
Description: Non-invasive brain stimulation (sham)
Study: NCT01085188

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UCC
Description: recommendation made by discharge counselor upon leaving residential treatment to attend nearest outpatient clinic.
Study: NCT02489214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donafenib tosilate tablets
Description: 200mg bid
Study: NCT03542682

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quick Bolus
Description: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via quick bolus of 15 units per minute during a euglycemic clamp.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quick Bolus
Description: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via quick bolus of 15 units per minute during a euglycemic clamp.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bolus
Description: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via standard bolus of 1.5 units per minute during a euglycemic clamp.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bolus
Description: Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via standard bolus of 1.5 units per minute during a euglycemic clamp.
Study: NCT00642330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral ibuprofen
Description: one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous ibuprofen
Description: one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
Study: NCT04792294

Intervention type: DEVICE
Intervention: Extracorporeal photopheresis
Description: ECP can be used as second-line treatment in patients unresponsive to azithromycin. ECP has been firstly developed for treatment of cutaneous T cell lymphomas and later used in a variety of other indications including solid organ transplantation. The process starts with leukapheresis, followed by incubation of the isolated cells with 8-methoxypsoralen (8-MOP) and subsequent activation of 8-MOP with ultraviolet A radiation. At the end, the cells are reinfused into the patient. 8-MOP is a biologically inert substance, but in the presence of UVA light it cross-links DNA by forming covalent bonds with pyrimidine bases and causes apoptosis.
Study: NCT00407355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection of ranibizumab .3 dose
Description: PRN every 30 days withing retreatment criteria

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection of Ranibizumab .5 dose
Description: Intravitreal injection of Ranibizumab .5 dose every 30 days PRN with retreatment criteria
Study: NCT01916772

Intervention type: OTHER
Intervention: no interventions
Description: no interventions
Study: NCT02607215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: 25 mg/m2, D1, D8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 25 mg/m2, D1, D8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDP
Description: 75 mg/m2, D1
Study: NCT03810989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: infra-red sauna
Description: During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of infra-red sauna of 15 minutes duration separated by ten minutes rest outside the sauna.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: argometer and treadmill
Description: During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of physical exercise (by treadmill and argometer) of 20-30 minutes duration separated by 10 minutes rest.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: combination of sauna and hot bath
Description: During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of infra-red sauna as the first group then the patients will be immersed up to neck for one hour in water at 37-43 C.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: combination of sauna and hot bath
Description: During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of infra-red sauna as the first group then the patients will be immersed up to neck for one hour in water at 37-43 C.
Study: NCT05003362

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT
Description: mindfulness intervention for patients with pain/migraine
Study: NCT01682044

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study: NCT02689102

Intervention type: DEVICE
Intervention: Probe based optical techniques
Description: During the diagnostic bronchoscopy, optical biopsy of the mucosa and alveolar compartment will be conducted by two different probe based optical techniques (Confocal Laser Endomicroscopy (Mauna Kea technologies) and Optical Coherence Tomography (St Jude Medical)). After the study measurements a biopsy will be obtained in the same area.
Study: NCT01482390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will receive a total daily dose of 1000 milligrams (mg) (for participants weighing less than \[\<\] 75 kg) or 1200 mg (for participants weighing greater than or equal to \[\>=\] 75 kg) orally for 24 or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will receive a total daily dose of 1000 milligrams (mg) (for participants weighing less than \[\<\] 75 kg) or 1200 mg (for participants weighing greater than or equal to \[\>=\] 75 kg) orally for 24 or 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Participants will receive a total daily dose of 1000 milligrams (mg) (for participants weighing less than \[\<\] 75 kg) or 1200 mg (for participants weighing greater than or equal to \[\>=\] 75 kg) orally for 24 or 48 weeks.
Study: NCT02783352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic rotator cuff repair
Description: arthroscopic rotator cuff repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous micro-fragmented adipose tissue
Description: injection of autologous micro-fragmented adipose tissue (10 mL) after arthroscopic rotator cuff repair, in dry arthroscopy condition
Study: NCT04236856

Intervention type: DEVICE
Group type: OTHER
Intervention: Robotic Endovascular Procedure
Description: After providing written informed consent, subjects with cerebral aneurysms may have their aneurysm treated using the CorPath GRX System.
Study: NCT04546074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and Imatinib mesylate
Description: In Phase Ib study:~Level 1: Imatinib mesylate 200mg QD + Pembrolizumab 200mg Q3W, Level 2: Imatinib mesylate 400mg QD + Pembrolizumab 200mg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and Imatinib mesylate
Description: In Phase II study, eligible patients receive the dose determined in phase Ib cohort.
Study: NCT04207983

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EYS606
Description: EYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EYS606
Description: EYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle
Study: NCT01482390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants will receive a total daily dose of 1000 milligrams (mg) (for participants weighing less than \[\<\] 75 kg) or 1200 mg (for participants weighing greater than or equal to \[\>=\] 75 kg) orally for 24 or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mericitabine
Description: Participants will receive mericitabine 1000 mg orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mericitabine
Description: Participants will receive mericitabine 1000 mg orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mericitabine
Description: Participants will receive mericitabine 1000 mg orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a
Description: Participants will receive 180 micrograms (mcg) subcutaneous injection once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a
Description: Participants will receive 180 micrograms (mcg) subcutaneous injection once weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon Alfa-2a
Description: Participants will receive 180 micrograms (mcg) subcutaneous injection once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a
Description: Participants will receive 180 micrograms (mcg) subcutaneous injection once weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching to mericitabine orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to mericitabine orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Participants will receive telaprevir 750 mg orally three times daily.
Study: NCT01482390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Participants will receive telaprevir 750 mg orally three times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir
Description: Participants will receive telaprevir 750 mg orally three times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Participants will receive telaprevir 750 mg orally three times daily.
Study: NCT01599364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir, ritonavir, lamivudine
Description: Lamivudine 300 mg 1 pill once-a-day, atazanavir 300 mg 1 pill with ritonavir 100 mg 1 pill once-a-day, taken together orally with a light meal
Study: NCT02906384

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hippocampus avoidance
Description: conformal avoidance of the hippocampal neural stem-cell compartment during prophylactic cranial irradiation
Study: NCT00737399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling with Emotional Freedom Techniques (EFT)
Description: Two series of four sessions of phone support group coaching instruction in the use of EFT
Study: NCT04316702

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric oxygen therapy (HBOT) treatment
Description: 60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week. Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cymbalta / Lyrica - Drug treatment
Description: one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica. Two medications currently licensed for the treatment of FM in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg twice a day, at morning and at bedtime, while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning).
Study: NCT01890629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin
Study: NCT03708562

Intervention type: DEVICE
Group type: OTHER
Intervention: everlinQ endoAVF System
Description: The everlinQ device is a single-use disposable device. The everlinQ catheter system consists of two flexible, magnetic catheters. Once the catheters are properly inserted and aligned, the magnets contained in each catheter attract to one another, approximating the vessels while simultaneously aligning the electrode with the backstop. Radiofrequency (RF) energy is delivered to the electrode whereby the arterio-venous fistula (AVF) is created.
Study: NCT00958997

Intervention type: DRUG
Intervention: 18F-FP-DTBZ (18F-AV-133)
Description: The subjects will receive a single IV bolus of approximately 10 mCi 18F-AV-133.(Injection will contain no more than 25 µg of non-radiolabeled 19F-AV-133).

Intervention type: DRUG
Intervention: 18F-FP-DTBZ (18F-AV-133)
Description: The subjects will receive a single IV bolus of approximately 10 mCi 18F-AV-133.(Injection will contain no more than 25 µg of non-radiolabeled 19F-AV-133).

Intervention type: BIOLOGICAL
Intervention: Arginine-hydrochloride
Description: A bolus injection of 5g of 10% arginine-hydrochloride will be given over a period of 1 minute.

Intervention type: BIOLOGICAL
Intervention: Arginine-hydrochloride
Description: A bolus injection of 5g of 10% arginine-hydrochloride will be given over a period of 1 minute.
Study: NCT02052765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG continuous recording (Analyze ST)
Description: During the ajmaline test, continuous ECG recording was forced to record ST shift
Study: NCT00799773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Dose of 375 mg/m2, given intravenously, repeated at 1-week intervals for a total of four doses

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Description: Target volume of 1.25 plasma volume replacement; fresh frozen plasma (FFP) is the required replacement fluid; provided daily until platelet counts are normal and signs of tissue damage have improved.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasma exchange
Description: Target volume of 1.25 plasma volume replacement; fresh frozen plasma (FFP) is the required replacement fluid; provided daily until platelet counts are normal and signs of tissue damage have improved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: 1 mg/kg of prednisone (or equivalent) each day until plasma exchange is stopped

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: 1 mg/kg of prednisone (or equivalent) each day until plasma exchange is stopped
Study: NCT01185301

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Pre-filled syringe every other week

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Pre-filled syringe every other week

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Pre-filled syringe every other week

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Pre-filled syringe every other week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: weekly oral capsule dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: weekly oral capsule dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: weekly oral capsule dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: weekly oral capsule dosing
Study: NCT01191216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-methyl-d-tryptophan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Study: NCT00789165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quinidine
Description: quinidine at highest tolerated dose. Expected doses are hydroquinidine 600 - 900 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quinidine
Description: quinidine at highest tolerated dose. Expected doses are hydroquinidine 600 - 900 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: no therapy
Description: No therapy; this is not a placebo-controlled trial
Study: NCT02970864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polynerve
Description: Polymer biomaterial nerve conduit